tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ANVS Stock Latest News

Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
Company AnnouncementsAnnovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
1d ago
8K
ANVS
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
PremiumThe Fly
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
1d ago
ANVS
Annovis Bio Hosts Regulation FD Investor Information Webinar
PremiumCompany Announcements
Annovis Bio Hosts Regulation FD Investor Information Webinar
16d ago
8K
ANVS
Annovis Bio reports open-label extension study for Parkinson’s disease patients
PremiumThe Fly
Annovis Bio reports open-label extension study for Parkinson’s disease patients
2M ago
ANVS
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
PremiumCompany Announcements
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
2M ago
ANVS
Annovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap
PremiumRatingsAnnovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap
3M ago
ANVS
Annovis announces FDA meeting to discuss PDD program
Premium
The Fly
Annovis announces FDA meeting to discuss PDD program
3M ago
ANVS
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
Premium
The Fly
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
3M ago
ANVS
Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress
PremiumRatings
Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress
3M ago
ANVS
Annovis Bio Inc. Reports Q3 2025 Financial Results
PremiumCompany Announcements
Annovis Bio Inc. Reports Q3 2025 Financial Results
3M ago
ANVS
Annovis Bio reports Q3 EPS (37c) vs. (97c) last year
PremiumThe Fly
Annovis Bio reports Q3 EPS (37c) vs. (97c) last year
3M ago
ANVS
Annovis Bio sees cash runway to 3Q26
PremiumThe Fly
Annovis Bio sees cash runway to 3Q26
3M ago
ANVS
Optimistic Buy Rating for Annovis Bio Amid Promising Alzheimer’s Clinical Developments
PremiumRatingsOptimistic Buy Rating for Annovis Bio Amid Promising Alzheimer’s Clinical Developments
3M ago
ANVS
Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD
Premium
The Fly
Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD
3M ago
ANVS
Annovis Bio Announces Securities Purchase Agreement
Premium
Company Announcements
Annovis Bio Announces Securities Purchase Agreement
4M ago
8K
ANVS
Annovis Bio prices 1.67M shares at $2.05 in registered direct offering
PremiumThe Fly
Annovis Bio prices 1.67M shares at $2.05 in registered direct offering
4M ago
ANVS
Annovis Bio Announces $6M Stock Offering
PremiumCompany Announcements
Annovis Bio Announces $6M Stock Offering
4M ago
8K
ANVS
Promising Potential of Annovis Bio’s Buntanetap in Alzheimer’s Treatment Justifies Buy Rating
PremiumRatings
Promising Potential of Annovis Bio’s Buntanetap in Alzheimer’s Treatment Justifies Buy Rating
4M ago
ANVS
Annovis Bio prices 4M shares at $1.50 in registered direct offering
PremiumThe Fly
Annovis Bio prices 4M shares at $1.50 in registered direct offering
4M ago
ANVS
Annovis Bio announces new results from Phase 2/3 AD study of buntanetap
PremiumThe FlyAnnovis Bio announces new results from Phase 2/3 AD study of buntanetap
4M ago
ANVS
Annovis Bio appoints Guerin as Chief Financial Officer
Premium
The Fly
Annovis Bio appoints Guerin as Chief Financial Officer
5M ago
ANVS
Annovis Bio announces publication of new article in Biomolecules on buntanetap
Premium
The Fly
Annovis Bio announces publication of new article in Biomolecules on buntanetap
5M ago
ANVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >